Ipsen’s First Quarter 2013 Sales

Published: Apr 25, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Regulatory News:

Commenting on the first quarter 2013 performance, Marc de Garidel, Chairman and Chief Executive Officer of Ipsen said: “Ipsen is off to a good start this year with a solid specialty care growth, up 8.0%, notably driven by the good performance of Somatuline®. Moreover, primary care proved resilient with strong growth of Smecta® sales and international sales.” Marc de Garidel added : “Despite supply shortage issues with Increlex®, Ipsen confirms its 2013 guidance, both in terms of sales and recurring adjusted3 operating margin.”

Help employers find you! Check out all the jobs and post your resume.

Back to news